posted on 2021-01-12, 15:05authored byLovika Mittal, Mitul Srivastava, Anita Kumari, Rajiv K. Tonk, Amit Awasthi, Shailendra Asthana
The
dynamics and plasticity of the PD-1/PD-L1 axis are the bottlenecks
for the discovery of small-molecule antagonists to perturb this interaction
interface significantly. Understanding the process of this protein–protein
interaction (PPI) is of fundamental biological interest in structure-based
drug designing. Food and Drug Administration (FDA)-approved anti-PD-1
monoclonal antibodies (mAbs) are the first-in-class with distinct
binding modes to access this axis clinically; however, their mechanistic
aspects remain elusive. Here, we have unveiled the interactive interfaces
with PD-L1 and mAbs to investigate the native plasticity of PD-1 at
global (structural and dynamical) and local (residue side-chain orientations)
levels. We found that the structural stability and coordinated Cα movements are increased in the presence of PD-1’s
binding partners. The rigorous analysis of these PPIs using computational
biophysical approaches revealed PD-1ʼs intrinsic plasticity,
its concerted loops’ movement (BC, FG, and CC′), distal
side-chain motions, and the thermodynamic landscape, which are perturbed
remarkably from its unbound to bound states. Based on intra-/inter-residues’
contact networks and energetics, the hot-spots have
been identified that were found to be essential to arrest the dynamical
motions of PD-1 significantly for the rational design of therapeutic
agents by mimicking the mAbs mechanism.